Literature DB >> 21303801

European cancer mortality predictions for the year 2011.

M Malvezzi1, A Arfé2, P Bertuccio3, F Levi4, C La Vecchia5, E Negri2.   

Abstract

BACKGROUND: Mortality figures become available after some years.
MATERIALS AND METHODS: Using the World Health Organization mortality and population data, we estimated numbers of deaths in 2011 from all cancers and selected sites for the European Union (EU) and six major countries, by fitting a joinpoint model to 5-year age-specific numbers of deaths. Age-standardized rates were computed using EUROSTAT population estimates.
RESULTS: The predicted number of cancer deaths in the EU in 2011 was 1,281,436, with standardized rates of 143/100,000 men and 85/100,000 women. Poland had the highest rates, with smaller falls over recent periods. Declines in mortality for major sites including stomach, colorectum, breast, uterus, prostate and leukemias, plus male lung cancer, will continue until 2011, and a trend reversal or a leveling off is predicted where upward trends were previously observed. Female lung cancer rates are increasing in all major EU countries except the UK, where it is the first cause of cancer death, as now in Poland. The increasing pancreatic cancer trends in women observed up to 2004 have likely leveled off.
CONCLUSIONS: Despite falls in rates, absolute numbers of cancer deaths are stable in Europe. The gap between Western and former nonmarket economy countries will likely persist.
© The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology.

Entities:  

Mesh:

Year:  2011        PMID: 21303801     DOI: 10.1093/annonc/mdq774

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  42 in total

1.  Expression of DNA damage checkpoint 53BP1 is correlated with prognosis, cell proliferation and apoptosis in colorectal cancer.

Authors:  Jianping Bi; Ai Huang; Tao Liu; Tao Zhang; Hong Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

2.  Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.

Authors:  Yuan Chen; Shao-An Xue; Shahriar Behboudi; Goran H Mohammad; Stephen P Pereira; Emma C Morris
Journal:  Clin Cancer Res       Date:  2017-07-14       Impact factor: 12.531

3.  Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.

Authors:  Ewelina Gumbarewicz; Jarogniew J Luszczki; Anna Wawruszak; Magdalena Dmoszynska-Graniczka; Aneta J Grabarska; Agata M Jarząb; Krzysztof Polberg; Andrzej Stepulak
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

4.  Gene signatures in breast cancer: current and future uses.

Authors:  Enrique Espinosa Arranz; Juan Ángel Fresno Vara; Angelo Gámez-Pozo; Pilar Zamora
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 5.  Colorectal cancer surgery in the very elderly patient: a systematic review of laparoscopic versus open colorectal resection.

Authors:  Laurence Devoto; Valerio Celentano; Richard Cohen; Jim Khan; Manish Chand
Journal:  Int J Colorectal Dis       Date:  2017-06-30       Impact factor: 2.571

Review 6.  How can grafted breast cancer models be optimized?

Authors:  Séverine Mollard; Yoanne Mousseau; Yasser Baaj; Laurence Richard; Jeanne Cook-Moreau; Jacques Monteil; Benoît Funalot; Franck G Sturtz
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

7.  Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project.

Authors:  Christine A Iacobuzio-Donahue
Journal:  Gut       Date:  2011-07-11       Impact factor: 23.059

8.  Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre.

Authors:  Giuliano Barugola; Stefano Partelli; Stefano Crippa; Giovanni Butturini; Roberto Salvia; Nora Sartori; Claudio Bassi; Massimo Falconi; Paolo Pederzoli
Journal:  HPB (Oxford)       Date:  2013-03-12       Impact factor: 3.647

9.  Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.

Authors:  Jesús A Junco Barranco; Robert P Millar; Franklin Fuentes; Eddy Bover; Eulogio Pimentel; Roberto Basulto; Lesvia Calzada; Rolando Morán; Ayni Rodríguez; Hilda Garay; Osvaldo Reyes; Maria D Castro; Ricardo Bringas; Niurka Arteaga; Henio Toudurí; Mauricio Rabassa; Yairis Fernández; Andrés Serradelo; Eduardo Hernández; Gerardo E Guillén
Journal:  Oncol Lett       Date:  2016-06-07       Impact factor: 2.967

10.  Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.

Authors:  A Zeuner; F Francescangeli; P Contavalli; G Zapparelli; T Apuzzo; A Eramo; M Baiocchi; M L De Angelis; M Biffoni; G Sette; M Todaro; G Stassi; R De Maria
Journal:  Cell Death Differ       Date:  2014-07-18       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.